Indaptus Therapeutics is a clinical-stage biotechnology company developing systemically-administered anti-cancer and anti-viral immunotherapies. Its patented technology uses attenuated and killed, non-pathogenic, Gram-negative bacteria designed for reduced intravenous toxicity while activating innate and adaptive immunity. Its lead candidate, Decoy20, was evaluated in a Phase 1 trial for advanced solid tumors, including in combination with BeiGene's anti-PD-1 antibody Tislelizumab. The company has discontinued clinical enrollment and is evaluating strategic options including potential acquisition of a target company.
Q2 FY2026 — expected 2026-09-15
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-17 | 2025-12-31 | 0001493152-26-010585 | EDGAR | 84K words |
| 2025-03-13 | 2024-12-31 | 0001493152-25-010136 | EDGAR | 76K words |
| 2024-03-13 | 2023-12-31 | 0001493152-24-009769 | EDGAR | 60K words |
| 2023-03-17 | 2022-12-31 | 0001493152-23-008010 | EDGAR | 61K words |
| 2022-03-21 | 2021-12-31 | 0001493152-22-007319 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-13 | 2026-06-30 | 0001493152-26-037579 | EDGAR | 17K words |
| 2025-11-12 | 2025-09-30 | 0001493152-25-021759 | EDGAR | 18K words |
| 2025-08-13 | 2025-06-30 | 0001641172-25-023333 | EDGAR | 17K words |
| 2025-05-14 | 2025-03-31 | 0001641172-25-010099 | EDGAR | 14K words |
| 2024-11-12 | 2024-09-30 | 0001493152-24-044537 | EDGAR | 42K words |
| 2024-08-12 | 2024-06-30 | 0001493152-24-031158 | EDGAR | 41K words |
| 2024-05-08 | 2024-03-31 | 0001493152-24-018162 | EDGAR | 39K words |
| 2023-11-06 | 2023-09-30 | 0001493152-23-039523 | EDGAR | 41K words |
| 2023-08-14 | 2023-06-30 | 0001493152-23-028059 | EDGAR | 41K words |
| 2023-05-11 | 2023-03-31 | 0001493152-23-016268 | EDGAR | 39K words |
| 2022-11-10 | 2022-09-30 | 0001493152-22-031392 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0001493152-22-021562 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-10 | 0001493152-26-042037 | EDGAR | 13K words |
| 2026-09-04 | 0001493152-26-041532 | EDGAR | 1K words |
| 2026-09-01 | 0001493152-26-040926 | EDGAR | 23K words |
| 2026-08-13 | 0001493152-26-037574 | EDGAR | 3K words |
| 2026-04-03 | 0001493152-26-015079 | EDGAR | 1K words |
| 2026-03-24 | 0001493152-26-012372 | EDGAR | 2K words |
| 2026-02-27 | 0001493152-26-008326 | EDGAR | 2K words |
| 2026-02-12 | 0001493152-26-006330 | EDGAR | 4K words |
| 2026-01-20 | 0001493152-26-002850 | EDGAR | 1K words |
| 2026-01-08 | 0001493152-26-001004 | EDGAR | 1K words |
116 total filings indexed. 89 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001857044 |
| Ticker | INDP |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.indaptusrx.com |
| Listed | 2021-08-04 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/INDP (~200 tokens, structured JSON with cryptographic provenance)